Heterogeneous Or Solid Phase Assay System (e.g., Elisa, Etc.) Patents (Class 435/7.92)
  • Patent number: 10656163
    Abstract: The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: May 19, 2020
    Assignee: Wallac Oy
    Inventors: Tarja Ahola, Heikki Kouru, Mikko Sairanen
  • Patent number: 10655163
    Abstract: Described herein are methods, compositions, kits and systems for multiplexed detection of target molecules from a sample. In some embodiments, the methods, compositions, kits and systems can be used to perform multiplexed protein analysis of a sample (e.g., a sample comprising a small number of cells or a single-cell sample). In some embodiments, the same sample subjected to a multiplexed protein analysis using the methods, compositions, kits and systems described herein can also be subjected to a nucleic acid (e.g., RNAs, microRNAs, and/or DNA) analysis, thereby creating an integrated expression profiling from a limited amount of sample.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: May 19, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Ralph Weissleder, Sarit S. Agasti, Vanessa M. Peterson, Adeeti Ullal
  • Patent number: 10634671
    Abstract: The invention relates to a method for in situ imaging of samples by cycle multiplexing that enables imaging of various molecular targets through multi-molecular read-outs on the same sample in a rapid, highly sensitive and reliable manner. The invention is further related to imaging buffers preventing the degradation of the sample and of the imaging reagents, which are particularly useful in a method of in situ imaging of samples by cycle multiplexing according to the invention.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: April 28, 2020
    Assignee: LUNAPHORE TECHNOLOGIES SA
    Inventors: Ata Tuna Ciftlik, Diego Gabriel Dupouy, Pierre Joris, Martin Gijs
  • Patent number: 10604699
    Abstract: Provided are an organic rare-earth solid micelle, a preparation method therefor, and a method for increasing the photoelectric conversion efficiency of a solar battery. A small organic conjugated ligand is taken as a first ligand, an amphiphilic diblock polymer is taken as a second ligand, and the first ligand and the second ligand are mixed and doped with a rare-earth chloride solution, and self-assembled to form an organic rare-earth solid micelle, whereby the fluorescence emission intensity and the fluorescence efficiency of the rare-earth element are improved. Next, the prepared organic rare-earth solid micelle is spin coated on an ITO layer of a solar battery, to prepare a solar battery with the organic rare-earth solid micelle. Therefore the sunlight absorption of a cell is increased, and the photoelectric conversion efficiency is improved. The preparation process is simple, low in cost, high in photoelectric conversion efficiency, and environmentally friendly.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: March 31, 2020
    Assignee: Qingdao University
    Inventors: Jianguo Tang, Die Wang, Wenfei Shen, Xinzhi Wang, Yao Wang, Linjun Huang, Jixian Liu, Jiqing Jiao, Yanxin Wang, Wei Wang, Xiaolin Zhang, Fanchen Bu, Jing Wang, Yan Song, Huihui Yang, Xingqin Xu, Laurence A. Belfiore
  • Patent number: 10564151
    Abstract: The present invention relates to a method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: February 18, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Michael Schraeml, Markus Roessler, Michael Gerg
  • Patent number: 10564084
    Abstract: Disclosed is a process and device allowing for fast measurements of the physicochemical properties of amphiphiles (lipids, surfactants, soaps, . . . ). A Marangoni flow is created and characterized using amphiphiles to be characterized. The observed flow is characterized, and using the disclosed process, one can deduce from this measurement many important physicochemical parameters of the amphiphiles such as their critical micellar concentration. Compared to existing techniques, the disclosed process offers the advantage that it requires a single experiment to deduce the parameters, when other techniques (pendant drop method, conductometry, etc . . . ) require the measurement of a quantity (interfacial tension, conductometry) against a systematically varied parameter (amphiphile concentration, . . . ). The disclosed process and devices are ideal to characterize and/or screen rapidly amphiphiles molecules based on their interaction with a solvent.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: February 18, 2020
    Assignees: THE TRUSTEES OF PRINCETON UNIVERSITY, CNRS-CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE RENNES I, CHANCELLOR, MASTERS & SCHOLARS OF UNIV. OF OXFORD
    Inventors: Matthieu Roche, Howard A. Stone, Isabelle Cantat, Arnaud Saint-Jalmes, Ian Griffiths, Sebastien Le Roux, Zhen Zhen Li
  • Patent number: 10514604
    Abstract: Topcoat compositions are provided that are suitably applied above a photoresist composition. Preferred topcoat compositions comprise a first polymer that comprises (i) first units comprising a nitrogen-containing moiety that comprises an acid-labile group; and (ii) second units that (1) comprise one or more hydrophobic groups and (2) are distinct from the first units.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 24, 2019
    Assignee: Rohm and Haas Electronic Materials Korea Ltd.
    Inventors: Chang-Young Hong, Eui-Hyun Ryu, Min-Kyung Jang, Dong-Yong Kim, Jae Yun Ahn
  • Patent number: 10509031
    Abstract: A method for providing quality control on a lateral flow assay device or for triggering a process-related step, the device including a substrate having at least one sample receiving area, at least one reagent zone downstream and in fluid communication with the at least one sample receiving area, at least one detection zone downstream and in fluid communication with the at least one reagent zone and at least one wicking zone downstream of the at least one detection zone, each fluidly interconnected therewith along at least one fluid flow path. The detection material provided in the at least one reagent zone produces a detectable signal that can be tracked and monitored prior to the completion of at least one test being performed on the lateral flow assay device.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 17, 2019
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: Zhong Ding, James E. Robinson, David A. Tomasso, David A. Heavner
  • Patent number: 10509046
    Abstract: Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: December 17, 2019
    Assignee: Randox Laboratories Limited
    Inventors: Ivan McConnell, Peter Fitzgerald, Philip Lowry, Elouard Benchikh
  • Patent number: 10494436
    Abstract: The present invention relates to anti-PD-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have CDRs as provided in the enclosed sequences. Also part of the invention are nucleic acids encoding these antibodies, expression vectors comprising such nucleotide sequences and host cells that comprise said nucleotide sequences or expression vectors.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: December 3, 2019
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Carlos Ricardo Rodrigues Dos Reis
  • Patent number: 10466238
    Abstract: The present invention fitted in the medical-clinical sector, shows a method for monitoring the ingestion of gluten by measuring protein/gluten peptides present in fecal samples with antibodies against immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of these immunogenic peptides is controlled by immunological assays based on antibodies reactive against immunogenic gluten peptides that are resistant to proteolysis. These assays may be quantitative techniques ELISAs, or qualitative as rapid immunochromatographic assays, immunoblots, etc. These measures may also be applied to verify compliance with the gluten-free diet, to improve diagnosis in cases of refractory or severe symptoms of celiac disease in which a gluten-free diet is supposedly being respected, or to clinical research on the effectiveness of enzymatic therapies related with prolamin detoxification.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: November 5, 2019
    Assignee: UNIVERSIDAD DE SEVILLA
    Inventors: Carolina Sousa Martin, Isabel Comino Montilla, Ana Real Calderon, Santiago Vivas Alegre, Angel Cebolla Ramirez
  • Patent number: 10451636
    Abstract: The invention provides a method for screening for and detection of solid organ graft rejection in a subject that comprises assaying a patient sample of plasma, serum or blood from the subject for a protein marker identified herein. An elevated or reduced amount of marker present in the patient sample compared to a control sample is indicative of rejection, and identifies subjects in need of biopsy or modified treatment. The method can be used to screen for patients in danger of transplant rejection without having to undergo more costly, risky and invasive biopsy procedures.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: October 22, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Elaine F. Reed, Hans Albin Gritsch, Jeffrey Lorne Veale
  • Patent number: 10444182
    Abstract: According to one embodiment, a semiconductor device includes FET having a threshold changing according to a chemical state in a gate portion, a time-varying signal application section configured to apply a time-varying signal to at least one of a source, a drain and a back gate of the FET, and a signal reading section configured to read a change in the threshold of the FET resulting from the application of the time-varying signal as a signal.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: October 15, 2019
    Assignee: Kabushiki Kaisha Toshiba
    Inventor: Kaita Imai
  • Patent number: 10436800
    Abstract: Provided are methods of determining if a subject has a cardiac disorder or is at risk for developing a cardiac disorder.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: October 8, 2019
    Assignee: SARCOTEIN DIAGNOSTICS, LLC
    Inventors: Darryl Steven Shaw, Neil Gavin Shaw
  • Patent number: 10434137
    Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the the proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, including peptides and/or interfering RNA and/or lipidic compounds, the agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 8, 2019
    Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA
    Inventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suarez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gomez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcon Cama, Osvaldo Reyes Acosta
  • Patent number: 10422799
    Abstract: A problem to be solved by the present invention is to provide an immunochromatographic test strip and a detection method using immunochromatography avoiding aggregation of colloidal gold conjugates while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a blood-agglutinating agent and the colloidal gold conjugates as a detection reagent. To solve the problem, the present inventers reviewed a past reagent configuration itself from a completely different viewpoint rather than selecting type and amount of polyanions and, as a result of extensive study on each element, the inventers surprisingly found that aggregation of colloidal gold can be suppressed by using a certain buffer solution without using neutralization by polyanions.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 24, 2019
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Mayumi Yoshida, Mitsuaki Yamamoto, Shinya Yokokawa, Tomo Shimizu, Keigo Kono
  • Patent number: 10416156
    Abstract: A problem to be solved by the present invention is to provide an immunochromatographic test strip and a detection method using immunochromatography avoiding aggregation of colloidal gold conjugates while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a blood-agglutinating agent and the colloidal gold conjugates as a detection reagent. To solve the problem, the present inventers reviewed a past reagent configuration itself from a completely different viewpoint rather than selecting type and amount of polyanions and, as a result of extensive study on each element, the inventers surprisingly found that aggregation of colloidal gold can be suppressed by using a certain buffer solution without using neutralization by polyanions.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: September 17, 2019
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Mayumi Yoshida, Mitsuaki Yamamoto, Shinya Yokokawa, Tomo Shimizu, Keigo Kono
  • Patent number: 10392665
    Abstract: The disclosure provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. Also provided is a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 to determine the probability for preterm birth in the pregnant female.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: August 27, 2019
    Assignee: Sera Prognostics, Inc.
    Inventors: John Jay Boniface, Andrew Gassman, Jeff Flick, Chad Bradford, Ashoka Polpitiya, Tracey Cristine Fleischer, Durlin Edward Hickok, Paul Kearney, Gregory Charles Critchfield
  • Patent number: 10386276
    Abstract: Techniques for phosphoprotein detection, quantification, and purification using a chip-based pillar array are provided. In one aspect, a method for purifying a protein sample includes: introducing a mixture including the protein sample and an antibody to a nanoDLD array having a plurality of pillars separated by a gap g, wherein the antibody and proteins in the protein sample form antibody-protein complexes having a size that is greater than a size threshold of the nanoDLD array created by the gap g which permits size-based separation of the antibody-protein complexes as the mixture flows through the nanoDLD array; and collecting a purified protein sample containing the antibody-protein complexes from the nanoDLD array. A lab-on-a-chip (LOC) device including the nanoDLD array is also provided.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: August 20, 2019
    Assignee: International Business Machines Corporation
    Inventors: Stacey M. Gifford, Gustavo A. Stolovitzky, Benjamin H. Wunsch
  • Patent number: 10369564
    Abstract: Disclosed are devices, kits, compositions, and methods for collecting, transporting, and detecting toxicants, pathogens, and biomarkers in a biological sample. The devices, kits, compositions and methods may be utilized to collect and transport dried blood samples from a skin prick and detect toxicants, pathogens, and biomarkers in the dried blood samples.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: August 6, 2019
    Assignee: Northwestern University
    Inventors: William E. Funk, Thomas W. McDade, Andrew Unger
  • Patent number: 10364286
    Abstract: The invention relates to a novel use of monoclonal anti-alpha-synuclein antibodies. The antibodies can be used to prevent tau aggregation and thereby treating tauopathies such as Alzheimer's disease.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 30, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Karina Fog, Jeppe Falsig Pedersen
  • Patent number: 10359406
    Abstract: Disclosed are biomarkers for preeclampsia including elevated levels of free hemoglobin, including free fetal haemoglobin and the ratio of free fetal hemoglobin to total free hemoglobin. Also disclosed are methods of treating preeclampsia using a therapeutic agent that reduces free circulating hemoglobin levels.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: July 23, 2019
    Assignee: A1M PHARMA AB
    Inventors: Stefan Hansson, Bo Åkerström
  • Patent number: 10342471
    Abstract: A biological fluid sampling transfer device adapted to receive a multi-component blood sample is disclosed. After collecting the blood sample, the biological fluid sampling transfer device is able to separate a plasma portion from a cellular portion. After separation, the biological fluid sampling transfer device is able to transfer the plasma portion of the blood sample to a point-of-care testing device. The biological fluid sampling transfer device also provides a closed sampling and transfer system that reduces the exposure of a blood sample and provides fast mixing of a blood sample with a sample stabilizer. The biological fluid sampling transfer device is engageable with a blood testing device for closed transfer of a portion of the plasma portion from the biological fluid sampling transfer device to the blood testing device. The blood testing device is adapted to receive the plasma portion to analyze the blood sample and obtain test results.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: July 9, 2019
    Assignee: Becton, Dickinson and Company
    Inventors: Bradley M. Wilkinson, Daniel J. Marchiarullo, Gary D. Fletcher
  • Patent number: 10302657
    Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: May 28, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Barbara Denk, Martin Hund
  • Patent number: 10300108
    Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: May 28, 2019
    Assignees: Astute Medical, Inc., University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Paul McPherson, John A. Kellum
  • Patent number: 10267802
    Abstract: Cellular markers indicating a poor prognosis for ovarian cancer patients are disclosed. In particular, the invention relates to methods utilizing the frequency of a subset of cells in ovarian tumor tissue expressing vimentin, cMyc, or HE4, or any combination thereof, to predict an ovarian cancer patient will relapse.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 23, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jonathan Berek, Wendy Fantl, Veronica Gonzalez, Garry P. Nolan, Nikolay Samusik
  • Patent number: 10254279
    Abstract: A system and method includes a test container for detecting a target substance in a consumable sample, where the test container includes a test container body defining a test container top, a test container bottom opposing the test container top, a first chamber proximal the test container top, and a second chamber proximal the test container bottom, a magnetic diaphragm situated between the first chamber and the second chamber, the magnetic diaphragm obstructing flow of the consumable sample, and the magnetic diaphragm including a magnetic element embedded in the magnetic diaphragm, and a driving element geometrically complementary to the first chamber, the driving element including a consumable sample grinding feature protruding from a surface of the driving element.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: April 9, 2019
    Assignee: Nima Labs, Inc.
    Inventors: Scott Sundvor, Steven Portela, Jonathan Ward, John Walton, Jonathan William Kiel, Jeffrey Mekler, Shireen Yates, Jacob Mooney, Dane Weitmann, Joseph Horrell
  • Patent number: 10234462
    Abstract: The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: March 19, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Sara Arab, Georg Hess, Hendrik Huedig, Peter Liu, Ursula-Henrike Wienhues-Thelen
  • Patent number: 10222375
    Abstract: The machine is configured to perform an automated rapid plasma reagent (RPR) agglutination test or other agglutination test. The machine includes a sample rack with multiple sample locations thereon and a reagent rack for storing of reagent. A shaker assembly supports at least one microtiter plate or other well supporting structure thereon with a plurality of wells in the plate. An automated pipette accesses samples and reagent and deposits them within wells of the microtiter plate. The shaker assembly shakes multiple samples within the wells of the microtiter plate. Finally, a camera photographs the wells of the plate, preferably from above with a light source below and the plate at least partially transparent. The image is then analyzed in an automated fashion to determine whether a ring of contrast material has remained smooth indicative of a non-reactive sample or has agglutinated/clumped together indicative of a reactive sample.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: March 5, 2019
    Assignee: Gold Standard Diagnostics
    Inventors: Peter Van Praet, Jennifer Roth, John Griffiths
  • Patent number: 10213459
    Abstract: Mitochondrial compositions and therapeutic methods of using same. Compositions of partially purified functional mitochondria and methods of using the compositions to treat conditions which benefit from increased mitochondrial function by administering the compositions to a subject in need thereof.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: February 26, 2019
    Assignee: MINOVIA THERAPEUTICS LTD.
    Inventors: Natalie Yivgi-Ohana, Uriel Halavee
  • Patent number: 10202635
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Ephrin Type-A Receptor 2 (EPHA2) protein are provided that are particularly advantageous for quantifying the EPHA2 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: February 12, 2019
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
  • Patent number: 10195580
    Abstract: A method of creating a mask on a surface of a substrate is disclosed. The substrate comprises a plurality of spaced heating elements on or proximal to the surface. The method comprises applying a layer of masking material to the surface and employing the heating elements to apply energy to a phase change in the masking material at the selected sites such that it adheres to the surface or can be displaced from the surface to mask or unmask the selected sites respectively. A method of synthesising an array of molecules, an apparatus for selectively masking one or more sites on a surface and a semi-conductor chip that uses micro-heaters to modulate a masking layer on areas of the chip surface.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: February 5, 2019
    Assignee: EVONETIX LTD.
    Inventors: Daniel Arthur Hall, Christopher John Favero Jordan
  • Patent number: 10175258
    Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: January 8, 2019
    Assignee: RANDOX LABORATORIES LIMITED
    Inventors: Stephen Peter Fitzgerald, Paul John Innocenzi, Ivan Robert McConnell, Philip Andrew Lowry, Elouard Benchikh
  • Patent number: 10175250
    Abstract: The present invention relates to the identification of a novel biomarker for cardiac ischemia: nitrated cardiac troponin I. The present invention also provides methods for the identification and use of a nitrated cardiac troponin as a biomarker for the diagnosis, prognosis and treatment management of myocardial ischemia, with and without necrosis of heart muscle. Diagnosis and prognosis is conducted by determining the amount of nitrated cardiac troponin I in serum samples of subjects and the ratio of nitrated cardiac troponin I to non-nitrated cardiac troponin I in serum samples of subjects. This biomarker can be detected by immunoassay techniques and tandem mass spectrometry. The present invention further relates to peptides, antibodies, compositions, methods, techniques, tests and kits for the identification and quantification of nitrated cardiac troponin I in samples of subjects.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: January 8, 2019
    Inventors: Gabriela Venturini Da Silva, Alexandre Da Costa Pereira, José Eduardo Krieger, Deborah Schechtman, Pedro Lemos, Jeane Mike Tsutsui, Valdemir Melechco Carvalho, Karina Helena Morais Cardozo
  • Patent number: 10174370
    Abstract: The present invention relates to a non-destructive method for analyzing maternal DNA of a seed. In this method the DNA may be dislodged from the seed coat surface and may be used to collect information on the genome of the maternal parent of the seed. Also, the present invention provides a high throughput DNA analysis system for large plant populations.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: January 8, 2019
    Assignee: RIJK ZWAAN ZAADTEELT EN ZAADHANDEL B.V.
    Inventor: Cornelis Maria Petrus Van Dun
  • Patent number: 10126309
    Abstract: The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: November 13, 2018
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS
    Inventor: John E. Wiktorowicz
  • Patent number: 10107822
    Abstract: Methods, kits, and diagnostic devices are disclosed for diagnosing an invasive fungal infection in a subject by measuring a T-cell interferon gamma (IFN-?) response after exposure to a fungal antigen.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: October 23, 2018
    Assignee: The Johns Hopkins University
    Inventor: Kieren Marr
  • Patent number: 10101327
    Abstract: A serological assay with an improved linear range of detection is disclosed using a fusion protein system, such as an anti-cytokine/cytokine fusion protein (ACYF) system, for evaluating immune responses. Also disclosed are related compositions, fusion proteins, expression vectors, monoclonal antibodies, and kits for practicing the assay method of the present invention.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: October 16, 2018
    Assignee: Cornell University
    Inventor: Bettina Wagner
  • Patent number: 10101340
    Abstract: Described is a method of detecting a protein fragment in a urine sample and a serum sample. The protein fragment is a urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, or serum osteopontin fragment. The urine sample and the serum sample are obtained from the same individual.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: October 16, 2018
    Assignee: Bio Preventive Medicine Corp.
    Inventors: Wei-Ya Lin, Mary Ya-Ping Yeh, Tzu-Ling Tseng, Ping-Fu Cheng, Tsai-Wei Hsu, Hung-Yi Li, Yi-Ting Chen, Yuh-Feng Ling, Jin-Shuen Chen, Yen-Peng Li
  • Patent number: 10101319
    Abstract: The present invention relates to a method of identifying a subject with a Plasmodium infection. The present invention also relates to a method for monitoring a subject with a Plasmodium infection, for example, following treatment with an anti-malaria compound. Also provided are methods of identifying a compound to treat a Plasmodium infection.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: October 16, 2018
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Stephen Trowell, Amalia Berna, Benjamin Padovan, Vicki Locke
  • Patent number: 10067143
    Abstract: The present application relates to a method of assaying ubiquitination in a sample by combining ubiquitin together with a substrate in a sample containing UBE1, UbcH3, Skp2-isoform 1, Skp1, Cull, Rbx1, Cks1, CDK2 and Cyclin E1 under conditions suitable for ubiquitination to take place, exposing the sample to a labelled binding partner which is specific for the ubiquitin, and measuring the amount of ubiquitin bound to the substrate.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: September 4, 2018
    Assignee: ITI Scotland Limited
    Inventor: Jonathan Peter Clark
  • Patent number: 10067125
    Abstract: The invention relates to methods of reliably and quantitatively determining the amount of an analyte of interest in a fluid sample using a flow-induced assay, such as an immunochromatographic assay, in which spatiotemporal measurements are recorded during the course of the assay reaction, generating a spatiotemporal dataset, and subsequently analyzed. The invention also relates to a system incorporating instruments for recording spatiotemporal datasets (spatiotemporal data recorders), devices comprised of flow-induced assays configured for analysis on a spatiotemporal recorder, and programs for analyzing the recorded spatiotemporal datasets.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: September 4, 2018
    Inventor: Edward L Mamenta
  • Patent number: 10067127
    Abstract: An object of the present invention is to provide a method of detecting an analyte (antigen) in a sample by an antigen-antibody reaction with an antibody fragment including an antigen binding region for the analyte antigen (hereinafter “an antibody fragment comprising an antigen binding region for an analyte antigen” will simply be referred to as “an antibody fragment against antigen”), the method suppressing nonspecific reaction that is caused by antibody fragments. More specifically, provided is a method of detecting an analyte antigen in a sample by an antigen-antibody reaction with an antibody fragment against antigen, the method comprising the steps of: a) bringing a sample into contact with a denatured antibody fragment; and b) bringing the sample into contact with the antibody fragment immobilized on an insoluble carrier after the step of a), the method suppressing nonspecific reaction.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: September 4, 2018
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Chie Kataoka, Hiroshi Takahashi, Tadaaki Yoshida, Yoshimasa Banba
  • Patent number: 10040866
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: August 7, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
  • Patent number: 10041962
    Abstract: A sensing paper suitable for sensing a target substance is provided. The sensing paper includes a filter paper, a wax, and a plurality of fluorescent materials. The wax is printed on the filter paper, wherein the sensing paper has a plurality of opening patterns, and each of the opening patterns respectively exposes a portion of the filter paper. The plurality of fluorescent materials is attached to the portion of the filter paper that is exposed by each of the opening patterns. Each of the fluorescent materials emits fluorescence, and after the fluorescent materials react with the target substance, an intensity of the fluorescence emitted by the fluorescent materials is quenched.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: August 7, 2018
    Assignee: National Taiwan University
    Inventors: Huan-Tsung Chang, Yao-Te Yen, Yu-Syuan Lin
  • Patent number: 10028955
    Abstract: The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 24, 2018
    Assignee: Novartis AG
    Inventors: Michaela Kneissel, Vito Guagnano, Diana Graus Porta, Simon Wöhrle
  • Patent number: 10023609
    Abstract: A method of reducing aggregate content in a preparation having a target protein includes contacting the preparation with an alkyl cation to form a mixture, and contacting the mixture with at least one functionalized solid to remove excess alkyl cation.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: July 17, 2018
    Assignee: AGENCY FOR SCIENCE, RESEARCH AND TECHNOLOGY
    Inventor: Peter Stanley Gagnon
  • Patent number: 10001491
    Abstract: The present invention relates to a method for the in vitro determination of the radiosensitivity of a subject. More particularly, the invention relates to a method comprising a step of inducing an exogenous stress on a biological sample from a subject, followed by the comparison of the presence or level of at least one compound chosen in a group of defined compounds, in said biological sample and in a reference sample. The present invention also relates to the use of said at least one compound as predictive biomarker of the radio-sensitivity of a subject. The invention also relates to a kit for the detection of the presence or level of at least one of said compounds, usable in a method according to the invention.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: June 19, 2018
    Assignees: Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier, Institut Regional du Cancer de Montpellier
    Inventors: David Azria, Jerome Lacombe, Jerome Solassol, Alain Mange
  • Patent number: 9989523
    Abstract: The present invention provides kits, apparatus and methods for determining a biological condition in a mammalian subject, the method includes incubating a specimen from a patient with at least one composition in a kit for a predetermined period of time to form at least one reaction product, when the subject has said biological condition, and receiving an indication of the at least one reaction product responsive to at least one reporter element in the kit thereby providing the indication of the biological condition in the subject.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: June 5, 2018
    Assignee: LEUKODX LTD.
    Inventors: Harvey Lee Kasdan, Julien Meissonnier, Yoav Zuta, Bruce Davis, Micha Rosen, Yael Himmel, Yehoshua Broder
  • Patent number: 9968903
    Abstract: The invention features methods of making devices, or “platens”, having a high-density array of through-holes, as well as methods of cleaning and refurbishing the surfaces of the platens. The invention further features methods of making high-density arrays of chemical, biochemical, and biological compounds, having many advantages over conventional, lower-density arrays. The invention includes methods by which many physical, chemical or biological transformations can be implemented in serial or in parallel within each addressable through-hole of the devices. Additionally, the invention includes methods of analyzing the contents of the array, including assaying of physical properties of the samples.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: May 15, 2018
    Assignee: Life Technologies Corporation
    Inventors: Robert Hess, John Linton, Tanya S. Kanigan, Colin Brenan, Can Ozbal